- Home
- Equipment
- north america
- disease agents
Show results for
Refine by
Disease Agents Equipment Supplied In North America
6 equipment items found
Manufactured by:Hygieia Biological Laboratories based inWoodland, CALIFORNIA (USA)
Preventative health including vaccination is a key focus of good animal management. Hygieia offers inactivated autogenous bacterins and vaccines which are custom manufactured from disease agents specifically found at an individual ranch, zoo, or other animal facility. This allows the producer or owner to tailor a vaccine formulation to target only problem ...
Manufactured by:ASC Therapeutics based inMilpitas, CALIFORNIA (USA)
We are developing gene and cell-based therapies. Gene therapy is addition, alteration or removal of genes within cells and biological tissues to treat diseases. A correcting genetic agent can be delivered directly to the blood stream in vivo, or to the affected tissue in situ, or the targeted cells can be modified ex vivo and injected back to the patients. ...
Manufactured by:BioFactura, Inc. based inFrederick, MARYLAND (USA)
With a mortality rate of over 30%, smallpox is one of the most dangerous biological threats. It is person-to-person airborne communicable, highly contagious and exhibits a long pre-symptomatic phase (12-14 days) allowing undetectable spread worldwide. While smallpox was declared eradicated in 1980 by the World Health Organization after an extensive vaccination campaign, the threat of bioterrorism ...
Manufactured by:Qualigen Therapeutics, Inc. based inCarlsbad, CALIFORNIA (USA)
These same technologies are now the basis for the Company’s expansion into therapeutic applications for the treatment of cancer and infectious disease. Qualigen’s Selective Target Antigen Removal System (STARS), is an investigational therapeutic device product currently under development and evaluation that will utilize core expertise in advanced reagents and coatings ...
Manufactured by:Fate Therapeutics, Inc. based inSan Diego, CALIFORNIA (USA)
Despite the clinical benefit conferred by approved checkpoint inhibitor therapy against a variety of tumor types, these therapies are not curative and, in most cases, patients either fail to respond or their disease progresses on these agents. Resistance to checkpoint inhibitor therapy has been linked to impaired immune cell infiltration into the tumor, impaired ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
Lucatumumab (HCD122) is a fully human anti-CD40 antagonist monoclonal antibody, which blocks CD40/CD40L-mediated signaling. Lucatumumab efficiently mediates antibody-dependent cell-mediated cytotoxicity (ADCC) and clearance of tumor cells, can be used for refractory lymphomas, CLL and multiple myeloma ...